Navigation Links
DiagnoCure to host Q2 2008 earnings conference call and webcast
Date:6/5/2008

Ticker Symbol: CUR

QUEBEC CITY, June 5 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that the Company will release its second quarter 2008 financial results on June 13, 2008, at approximately 4:30 p.m. (ET). This release wil be followed by a conference call, which will be held on Monday, June 16, 2008, at 10:00 a.m. (ET). The conference will begin with a brief presentation, followed by a question-and-answer period.

The event will be webcast live on DiagnoCure's website at http://www.diagnocure.com through a link on the Investors page - Presentations and Conferences.

For those who wish to take part in the conference call for the Q&A period, please dial (514) 807-8791 (Montreal area), (416) 644-3414 (Toronto area) or the toll-free number (800) 733-7571.

For those unable to participate, a replay of the audio conference will also be available on DiagnoCure's website as of June 17, 2008, also through a link on the Investors page - Presentations and Conferences.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure is currently preparing to launch the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. In 2003, the Company entered into a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation test for PCA3, DiagnoCure's proprietary molecular marker highly specific to prostate cancer. The test is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information, visit http://www.diagnocure.com.

Forwardlooking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ material y from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.


'/>"/>
SOURCE DIAGNOCURE INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
2. Shamir Optical Industry Ltd. to Host Conference Call Announcing First Quarter 2008 Earnings Results
3. Mesa Labs Reports Record Year End Sales and Earnings
4. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
5. The Female Health Company Reports 267% Increase in Second Quarter Earnings
6. Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year
7. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
8. Met-Pro Corporation to Report First Quarter Earnings on May 22
9. Mental Illness Costs U.S. Billions in Lost Earnings
10. The Ensign Group, Inc. Reports First Quarter 2008 Earnings
11. Webcast Alert: Medial Saude S/A Announces First Quarter 2008 Earnings Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s ... ostomy patients, standing as living proof that attitude and determination can combine into ... issues that spike around the holidays. This campaign will offer patients a new-found ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... veterinarian diagnostic imaging systems and the first company to offer robotic ... a Heart at their tradeshow booth # 941 for the American Association of ...
(Date:12/2/2016)... Abilene, Texas (PRWEB) , ... December 02, 2016 , ... ... article that delves into how this current generation fits into Bible Prophecy. Yisrayl says ... lists various facts pointing to this conclusion, showing how the details line up exactly ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... meals to needy individuals and families from eight different sites throughout Miami-Dade and ... Day. Over 1,000 volunteers worked very hard on Thanksgiving morning by putting together ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... YORK , December 2, 2016 ... Braces & Support) is Expected to Gain a Significant Market ... to Orthopedic Ailments  ... , According to ... Study on Medical Implants Sterile Packaging: Clamshell Product Type Segment ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite and ... the Dow Jones Industrial Average managed to stay in green. ... which prompted Stock-callers this morning to look at the performances ... NUVA ), Smith & Nephew PLC (NYSE: SNN ... Cesca Therapeutics Inc. (NASDAQ: KOOL ). You can ...
(Date:12/2/2016)... -- The concept of rare diseases and the idea that ... has been taking shape in Europe ... initiatives related to orphan medicinal products have been emerging at ... states individually. Many member states in the EU have led ... medicinal products, the result of which took the shape of ...
Breaking Medicine Technology: